The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247 · Completed

Last updated 2026-05-28

This clinical trial tests whether adding insulin degludec to liraglutide and metformin helps lower blood sugar levels in adults with type 2 diabetes who need better control of their condition.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 346 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-10 · est. completion 2013-12

Where 132 sites · Canada, France, Germany, Israel, Italy, Serbia, South Africa, Ukraine, United Arab Emirates, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT01664247 ↗

Description as written by the study sponsor.

This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.

Treatments tested

insulin degludec Drug

Administered s.c. (under the skin) once daily. Dose individually adjusted.
placebo Drug

Administered s.c. (under the skin) once daily. Dose individually adjusted.
liraglutide Drug

Administered s.c. (under the skin) once daily. Dose: 1.8 mg.

Main thing measured	Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01664247 ↗